The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590

XDS

Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463

Refinement of Macromolecular Structures by the Maximum-Likelihood Method

Murshudov, G. N., Vagin, A. A., & Dodson, E. J. (1997) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444996012255 · Cited by 14,796

MOLREP : an Automated Program for Molecular Replacement

Vagin, A. A., & Teplyakov, A. (1997) · Journal of Applied Crystallography · doi:10.1107/s0021889897006766 · Cited by 4,756

The landscape of somatic copy-number alteration across human cancers

Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407

Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy

Czabotar, P. E., Lessene, G., Strasser, A., & Adams, J. M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3722 · Cited by 3,219

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,930

Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function

Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816

Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening

Mady, A. S. A., Liao, C., Bajwa, N., Kump, K. J., Abulwerdi, F. A., Lev, K. L., Miao, L., Grigsby, S. M., Perdih, A., Stuckey, J. A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-27899-9 · Cited by 19

The role of BCL-2 family proteins and therapeutic potential of BH3-mimetics in malignant pleural mesothelioma

Arulananda, S., Lee, E. F., Fairlie, W. D., & John, T. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1856660 · Cited by 19

Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation

Jurić, V., Hudson, L., Fay, J., Richards, C. E., Jahns, H., Verreault, M., Bielle, F., Idbaïh, A., Lamfers, M. L. M., Hopkins, A. M., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04050-7 · Cited by 19

In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets

Carlet, M., Völse, K., Vergalli, J., Becker, M., Herold, T., Arner, A., Senft, D., Jurinović, V., Liu, W., Gao, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25963-z · Cited by 19

Enhanced Apoptosis and Loss of Cell Viability in Melanoma Cells by Combined Inhibition of ERK and Mcl-1 Is Related to Loss of Mitochondrial Membrane Potential, Caspase Activation and Upregulation of Proapoptotic Bcl-2 Proteins

Peng, Z., Gillissen, B. F., Richter, A., Sinnberg, T. W., Schlaak, M. S., & Eberle, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054961 · Cited by 19

Discovery of a Myeloid Cell Leukemia 1 (Mcl-1) Inhibitor That Demonstrates Potent In Vivo Activities in Mouse Models of Hematological and Solid Tumors

Tarr, J. C., Salovich, J. M., Aichinger, M., Jeon, K., Veerasamy, N., Sensintaffar, J., Arnhof, H., Samwer, M., Christov, P. P., Kim, K., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01188 · Cited by 19

Molecular heterogeneity in diffuse large B-cell lymphoma and its implications in clinical diagnosis and treatment

Guo, L., Lin, P., Xiong, H., Tu, S., & Chen, G. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.01.001 · Cited by 20

Rationally derived drug combinations with the novel Mcl-1 inhibitor EU-5346 in breast cancer

Vallet, S., Fan, F., Malvestiti, S., Pecherstorfer, M., Sattler, M., Schneeweiß, A., Schulze‐Bergkamen, H., Opferman, J. T., Cardone, M. H., Jäger, D., et al. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-5022-5 · Cited by 19

Discovery of small molecule inhibitors through pharmacophore modeling, molecular docking, molecular dynamics simulation and experimental validation against myeloid cell leukemia-1 (Mcl-1)

Suleiman, M. R., Wang, H., Huang, D., Wang, H., Joseph, J., Huang, T., Zhang, F., Wang, J., & Cheng, M. (2020) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2020.1749132 · Cited by 19

Structure-Based Optimization of 3-Phenyl-N-(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide Derivatives as Selective Mcl-1 Inhibitors

Li, Y., Fan, W., Gong, Q., Tian, J., Zhou, M., Li, Q., Uwituze, L. B., Zhang, Z., Hong, R., & Wang, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00690 · Cited by 19

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Jayappa, K. D., Gordon, V. L., Morris, C. G., Wilson, B., Shetty, B. D., Cios, K. J., Arora, P. C., Isaac, K. M., Saha, S., Bender, T. P., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003944 · Cited by 19

Myeloid cell leukemia-1: a formidable barrier to anticancer therapeutics and the quest of targeting it

Sulkshane, P., & Teni, T. R. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00083 · Cited by 19

Rationale for a Combination Therapy Consisting of MCL1- and MEK-Inhibitors in Acute Myeloid Leukemia

Seipel, K., Schmitter, K., Bacher, U., & Pabst, T. (2019) · Cancers · doi:10.3390/cancers11111779 · Cited by 19

Key residues in the VDAC2-BAK complex can be targeted to modulate apoptosis

Yuan, Z., van Delft, M. F., Li, X., Sumardy, F., Smith, B. J., Huang, D. C. S., Lessène, G., Khakam, Y., Jin, R., He, S., et al. (2024) · PLoS Biology · doi:10.1371/journal.pbio.3002617 · Cited by 18

Relative importance of the anti-apoptotic versus apoptosis-unrelated functions of MCL-1 in vivo

Brinkmann, K., McArthur, K., Malelang, S., Gibson, L., Tee, A., Doomun, S. N. E., Rowe, C. L., Arandjelovic, P., Marchingo, J. M., D’Silva, D. B., et al. (2025) · Science · doi:10.1126/science.adw1836 · Cited by 18

RNA Pol II inhibition activates cell death independently from the loss of transcription

Harper, N. W., Birdsall, G. A., Honeywell, M. E., Ward, K. M., Pai, A. A., & Lee, M. J. (2025) · Cell · doi:10.1016/j.cell.2025.07.034 · Cited by 18

BAG3‐dependent expression of Mcl‐1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922

Wang, C. Y., Guo, S., Croft, A. J., Yan, X. G., Jin, L., Zhang, X. D., & Jiang, C. C. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22755 · Cited by 18

Discovery, development and application of drugs targeting BCL-2 pro-survival proteins in cancer

Lee, E. F., & Fairlie, W. D. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210749 · Cited by 18

Anti-apoptotic MCL1 Protein Represents Critical Survival Molecule for Most Burkitt Lymphomas and BCL2-negative Diffuse Large B-cell Lymphomas

Klanova, M., Kazantsev, D., Pokorna, E., Zikmund, T., Karolová, J., Behounek, M., Renešová, N., Sovilj, D., Kelemen, C. D., Helman, K., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0511 · Cited by 18

Super-Resolution Microscopy to Study Interorganelle Contact Sites

Nieto‐Garai, J. A., Olazar‐Intxausti, J., Anso, I., Lorizate, M., Terrones, O., & Contreras, F. ‐. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315354 · Cited by 20

Targeting MCL-1 triggers DNA damage and an anti-proliferative response independent from apoptosis induction

Adhikary, U., Paulo, J. A., Godes, M., Roychoudhury, S., Prew, M. S., Ben‐Nun, Y., Yu, E. W., Budhraja, A., Opferman, J. T., Chowdhury, D., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113176 · Cited by 19

Combination of MCL-1 and BCL-2 inhibitors is a promising approach for a host-directed therapy for tuberculosis

Arnett, E., Pahari, S., Wager, C. M. L., Hernandez, E., Bonifacio, J. R., Lumbreras, M., Renshaw, C. W., Montoya, M., Opferman, J., & Schlesinger, L. S. (2023) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2023.115738 · Cited by 20

Role of apoptosis in the development of autosomal dominant polycystic kidney disease (ADPKD)

Peintner, L., & Borner, C. (2017) · Cell and Tissue Research · doi:10.1007/s00441-017-2628-6 · Cited by 18

Increased expression of the tight junction protein TJP1/ZO-1 is associated with upregulation of TAZ-TEAD activity and an adult tissue stem cell signature in carfilzomib-resistant multiple myeloma cells and high-risk multiple myeloma patients

Riz, I., & Hawley, R. G. (2017) · Oncoscience · doi:10.18632/oncoscience.356 · Cited by 18

Predicting effective pro-apoptotic anti-leukaemic drug combinations using co-operative dynamic BH3 profiling

Grundy, M. A., Seedhouse, C., Jones, T., Elmi, L., Hall, M., Graham, A., Russell, N. H., & Pallis, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190682 · Cited by 18

BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock to Reprogramming

Kim, E. J. Y., Änkö, M., Flensberg, C., Majewski, I. J., Geng, F., Firas, J., Huang, D. C. S., van Delft, M. F., & Heath, J. K. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.12.019 · Cited by 19

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors

Yu, X., Dobrikov, M. I., Keir, S. T., Gromeier, M., Pastan, I. H., Reisfeld, R. A., Bigner, D. D., & Chandramohan, V. (2019) · PLoS ONE · doi:10.1371/journal.pone.0210608 · Cited by 18

BCL-W is dispensable for the sustained survival of select Burkitt lymphoma and diffuse large B-cell lymphoma cell lines

Diepstraten, S. T., Chang, C. W. T., Tai, L., Gong, J., Lan, P., Dowell, A. C., Taylor, G. S., Strasser, A., & Kelly, G. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019000541 · Cited by 18

Erratum: Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.

Ding, X., Zhang, Y., Huang, T., Xu, G., Peng, C., Chen, G., Kong, B., Frieß, H., Shen, S., Lv, Y., et al. (2019) · PubMed Central · Cited by 18

Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology

Li, K. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127717 · Cited by 18

The role of post-translational modifications in the regulation of MCL1

Li, S., Guo, W., & Wu, H. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.109933 · Cited by 19

Drimane Derivatives as the First Examples of Covalent BH3 Mimetics that Target MCL‐1

Daressy, F., Malard, F., Séguy, L., Guérineau, V., Apel, C., Dumontet, V., Robert, A., Groo, A., Litaudon, M., Bignon, J. S., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100011 · Cited by 18

Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins

Pal, P., Zhang, P., Poddar, S. K., & Zheng, G. (2022) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2022.2116311 · Cited by 18

Overcoming Steroid Resistance in T Cell Acute Lymphoblastic Leukemia

Goossens, S., & Vlierberghe, P. V. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002208 · Cited by 18

Targeting Mcl-1 inhibits survival and self-renewal of hepatocellular cancer stem-like cells

Zhang, H., Li, G., Chen, G., Zhang, Y., Pan, J., Tang, H., Li, J., Guo, W., & Zhang, S. (2018) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2018.11.004 · Cited by 18

Targeting Cancer's Achilles’ Heel: Role of BCL-2 Inhibitors in Cellular Senescence and Apoptosis

Anantram, A., & Degani, M. S. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0366 · Cited by 18

Structural basis of BAK sequestration by MCL-1 in apoptosis

Srivastava, S., Sekar, G., Ojoawo, A. M., Aggarwal, A., Ferreira, E., Uchikawa, E., Yang, M., Grace, C. R., Dey, R., Lin, Y.-L., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.03.013 · Cited by 17

Myeloid cell leukemin-1 inhibitors: a growing arsenal for cancer therapy

Zhu, P., Yu, Z.-Z., You, Q., & Jiang, Z. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.021 · Cited by 19

Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-Based Therapy

Walker, Z. J., Idler, B. M., Davis, L. N., Stevens, B. M., VanWyngarden, M. J., Ohlstrom, D. J., Bearrows, S. C., Hammes, A., Smith, C. A., Jordan, C. T., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2246 · Cited by 17

PP2A modulation overcomes multidrug resistance in chronic lymphocytic leukemia via mPTP-dependent apoptosis

Jayappa, K. D., Tran, B., Gordon, V. L., Morris, C. G., Saha, S., Farrington, C. C., O’Connor, C. M., Zawacki, K. P., Isaac, K. M., KESTER, M. A., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci155938 · Cited by 17

Unraveling the Complexity of Regulated Cell Death in Esophageal Cancer: from Underlying Mechanisms to Targeted Therapeutics

Zhang, H., Zhang, J., Luan, S., Liu, Z., Li, X., Liu, B., & Yuan, Y. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.85753 · Cited by 17

Development of recombinant protein-based nanoparticle systems for inducing tumor cell apoptosis: In vitro evaluation of their cytotoxic and apoptotic effects on cancer cells

Kaplan, Ö., Gök, M. K., Pekmez, M., Tayhan, S. E., Özgümüş, S., Gökçe, İ., & Arda, N. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105565 · Cited by 17

Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status

Dolníková, A., Kazantsev, D., Klánová, M., Pokorna, E., Sovilj, D., Kelemen, C. D., Tušková, L., Hoferkova, E., Mráz, M., Helman, K., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012906 · Cited by 17

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation

Kimman, T., Cuenca, M., Tieland, R. G., Rockx-Brouwer, D., Janssen, J., Motais, B., Slomp, A., Pleijte, C., Heijhuurs, S., Meringa, A. D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59818-8 · Cited by 17

Design, synthesis and biological evaluation of tyrosine derivatives as Mcl-1 inhibitors

Liu, L., Liu, R., Yang, X., Hou, X., & Fang, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112142 · Cited by 17

SUMOylation of MCL1 protein enhances its stability by regulating the ubiquitin-proteasome pathway

Li, S., Wang, J., Hu, G., Aman, S., Li, B., Li, Y., Xia, K., Yang, Y., Ahmad, B., Wang, M., et al. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109686 · Cited by 17

Pharmaceutical Drug Metformin and MCL1 Inhibitor S63845 Exhibit Anticancer Activity in Myeloid Leukemia Cells via Redox Remodeling

Valiulienė, G., Vitkevičienė, A., Skliutė, G., Borutinskaite, V. V., & Navakauskienė, R. (2021) · Molecules · doi:10.3390/molecules26082303 · Cited by 17

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells

Malyukova, A., Ujvári, D., Yektaei‐Karin, E., Zovko, A., Madapura, H. S., Keszei, M., Nagy, N., Lotfi, K., Björn, N., Wallvik, J., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04154-0 · Cited by 18

Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors

Sobol, B., Nieto, O. A., Eberlein, E. L., Scherr, A., Ismail, L., Kessler, A., Nader, L., Schwab, M., Hoffmeister‐Wittmann, P., Schmitt, N., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147850 · Cited by 17

NA1—115—7, from Zygogynum pancheri, is a new selective MCL-1 inhibitor inducing the apoptosis of hematological cancer cells but non-toxic to normal blood cells or cardiomyocytes

Daressy, F., Séguy, L., Favre, L., Corvaisier, S., Apel, C., Groo, A., Litaudon, M., Dumontet, V., Malzert‐Fréon, A., Desrat, S., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113546 · Cited by 17

BET Inhibition Induces Vulnerability to MCL1 Targeting Through Upregulation of Fatty Acid Synthesis Pathway in Breast Cancer

Yan, G., Luna, A., Wang, H., Bozorgui, B., Li, X., Sanchez, M., Dereli, Z., Kahraman, N., Kara, G., Chen, X., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2022.111304 · Cited by 18

Kröhnke pyridines: Rapid and facile access to Mcl-1 inhibitors

Conlon, I. L., Eker, D. V., Abdelmalak, S., Murphy, W. A., Bashir, H., Sun, M. A., Chauhan, J., Varney, K. M., Godoy‐Ruiz, R., Wilder, P. T., et al. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.03.050 · Cited by 17

Counting on Death – Quantitative aspects of Bcl‐2 family regulation

Hantusch, A., Rehm, M., & Brunner, T. (2018) · FEBS Journal · doi:10.1111/febs.14516 · Cited by 17

Structure-guided design of pyridoclax derivatives based on Noxa / Mcl-1 interaction mode

Hedir, S., Giorgi, M. D., Fogha, J., Pascale, M. D., Weiswald, L., Brotin, É., Marekha, B., Denoyelle, C., Denis, C., Suzanne, P., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.10.003 · Cited by 20

Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma

Wong, K. Y., & Chim, C. S. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13240 · Cited by 17

VDAC2 and Bak scarcity in liver mitochondria enables targeting hepatocarcinoma while sparing hepatocytes

Naghdi, S., Mishra, P., Roy, S. S., Weaver, D., Walter, L., Davies, E., Antony, A. N., Lin, X., Moehren, G., Feitelson, M. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56898-4 · Cited by 17

Mcl‐1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells

Sarif, Z., Tolksdorf, B., Fechner, H., & Eberle, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23253 · Cited by 16

Acute severe hypoxia induces apoptosis of human pluripotent stem cells by a HIF-1α and P53 independent mechanism

Mucci, S., Isaja, L., Rodríguez-Varela, M. S., Ferriol-Laffouillere, S. L., Marazita, M. C., Videla-Richardson, G. A., Sevlever, G. E., Scassa, M. É., & Romorini, L. (2022) · Scientific Reports · doi:10.1038/s41598-022-23650-7 · Cited by 17

Simultaneous Inhibition of Mcl-1 and Bcl-2 Induces Synergistic Cell Death in Hepatocellular Carcinoma

Michalski, M., Bauer, M., Walz, F., Tümen, D., Heumann, P., Stöckert, P., Gunckel, M., Kunst, C., Kandulski, A., Schmid, S. A., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11061666 · Cited by 20

FBXW7 and human tumors: mechanisms of drug resistance and potential therapeutic strategies

Wang, W., Jiang, K., Liu, X., Li, J., Zhou, W., Wang, C., Cui, J., & Liang, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1278056 · Cited by 16

Recent therapeutic advances in chronic lymphocytic leukemia

Bose, P., & Gandhi, V. V. (2017) · F1000Research · doi:10.12688/f1000research.11618.1 · Cited by 16

Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes

Jiao, Y., Davis, J. E., Rautela, J., Carrington, E. M., Ludford‐Menting, M., Goh, W., Delconte, R. B., Souza-Fonseca-Guimarães, F., Koldej, R. M., Gray, D. H. D., et al. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0228-y · Cited by 16

Rationally Designed Polypharmacology: α‐Helix Mimetics as Dual Inhibitors of the Oncoproteins Mcl‐1 and HDM2

Conlon, I. L., Drennen, B., Lanning, M. E., Hughes, S., Rothhaas, R., Wilder, P. T., MacKerell, A. D., & Fletcher, S. (2020) · ChemMedChem · doi:10.1002/cmdc.202000278 · Cited by 16

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA

Mallick, D. J., & Eastman, A. R. (2020) · Cancers · doi:10.3390/cancers12082298 · Cited by 16

Query-guided protein–protein interaction inhibitor discovery

Celis, S., Hóbor, F., James, T., Bartlett, G. J., Ibarra, A. Á., Shoemark, D. K., Hegedüs, Z., Hetherington, K., Woolfson, D. N., Sessions, R. B., et al. (2021) · Chemical Science · doi:10.1039/d1sc00023c · Cited by 17

Importance of Bcl-2-family proteins in murine hematopoietic progenitor and early B cells

Kurschat, C., Metz, A., Kirschnek, S., & Häcker, G. A. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04079-8 · Cited by 17

Mitochondrial E3 ubiquitin ligase MARCHF5 controls BAK apoptotic activity independently of BH3-only proteins

Huang, A. S., Chin, H. S., Reljić, B., Djajawi, T. M., Tan, I. K. L., Gong, J., Stroud, D. A., Huang, D. C. S., van Delft, M. F., & Dewson, G. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-022-01067-z · Cited by 17

Discovery and structure-activity relationship studies of N-substituted indole derivatives as novel Mcl-1 inhibitors

Luan, S., Ge, Q. P., Chen, Y., Dai, M., Yang, J., Li, K., Liu, D., & Zhao, L. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.028 · Cited by 16

Preferential targeting of MCL-1 by a hydrocarbon-stapled BIM BH3 peptide

Hadji, A., Schmitt, G. K., Schnorenberg, M. R., Roach, L. E., Hickey, C. M., Leak, L. B., Tirrell, M., & LaBelle, J. L. (2019) · Oncotarget · doi:10.18632/oncotarget.27262 · Cited by 16

Targeting the apoptotic Mcl-1-PUMA interface with a dual-acting compound

Liu, J., Tian, Z., Zhou, N., Liu, X., Liao, C., Lei, B., Li, J., Zhang, S., & Chen, H. (2017) · Oncotarget · doi:10.18632/oncotarget.17294 · Cited by 15

Cell-penetrating Alphabody protein scaffolds for intracellular drug targeting

Pannecoucke, E., Trimpont, M. V., Desmet, J., Pieters, T., Reunes, L., Demoen, L., Vuylsteke, M., Loverix, S., Vandenbroucke, K., Alard, P., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe1682 · Cited by 15

MEK and MCL-1 sequential inhibition synergize to enhance rhabdomyosarcoma treatment

Alcon, C., Martín, F., Prada, E., Mora, J., Soriano, A., Guillén, G., Gallego, S., Roma, J. M., Samitier, J., Villanueva, A., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00959-w · Cited by 18

Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells

Vera, M. B., Morris-Hanon, O., Nogueiras, G. I., Ripari, L. B., Esquivel, M. I., Perez-Castro, C., Romorini, L., Sevlever, G. E., Scassa, M. É., & Videla-Richardson, G. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-20910-4 · Cited by 16

Genetic mutations affecting mitochondrial function in cancer drug resistance

Lee, C., Park, S., & Yoon, S. K. (2023) · Genes & Genomics · doi:10.1007/s13258-022-01359-1 · Cited by 15

Macrocyclic Carbon-Linked Pyrazoles As Novel Inhibitors of MCL-1

Demin, S., Peschiulli, A., Velter, A. I., Vos, A. M., Boeck, B. D., Miller, B., Rombouts, F. J. R., Reuillon, T. D., Lento, W. E., Blanco, M. D., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00141 · Cited by 15

Non-genetic mechanisms of drug resistance in acute leukemias

Calderon, A., Han, C., Karma, S., & Wang, E. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.09.003 · Cited by 17

Apoptosis Inhibitor 5: A Multifaceted Regulator of Cell Fate

Abbas, H., Derkaoui, D. K., Jeammet, L., Adicéam, E., Tiollier, J., Sicard, H., Braun, T., & Poyet, J. (2024) · Biomolecules · doi:10.3390/biom14010136 · Cited by 16

Homoharringtonine synergizes with venetoclax in early T cell progenitor acute lymphoblastic leukemia: Bench and bed

Suo, S., Sun, S., Nguyen, L. X. T., Qian, J., Li, F., Zhao, D., Yu, W., Lou, Y., Zhu, H., Tong, H., et al. (2024) · Med · doi:10.1016/j.medj.2024.07.018 · Cited by 15

miR-146a down-regulation alleviates H2O2-induced cytotoxicity of PC12 cells by regulating MCL1/JAK/STAT pathway

Yang, X., Mao, X., Ding, X., Guan, F., Jia, Y., Luo, L., Li, B., Tan, H., & Cao, C. (2018) · Cell Biology and Toxicology · doi:10.1007/s10565-018-9424-2 · Cited by 15

Methotrexate significantly induces apoptosis by inhibiting STAT3 activation in NPM-ALK-positive ALCL cells

Uchihara, Y., Komori, R., Tago, K., Tamura, H., & Funakoshi‐Tago, M. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113666 · Cited by 15

Enhancing venetoclax activity in hematological malignancies

Satta, T., & Grant, S. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1789588 · Cited by 15

PROXIMA-1 beamline for macromolecular crystallography measurements at Synchrotron SOLEIL

Chavas, L. M. G., Gourhant, P., Guimarães, B. G., Isabet, T., Legrand, P., Lener, R., Montaville, P., Sirigu, S., & Thompson, A. (2021) · Journal of Synchrotron Radiation · doi:10.1107/s1600577521002605 · Cited by 15

Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss

He, S., Zimmerman, M. W., Layden, H. M., Berezovskaya, A., Etchin, J., Martel, M. W., Thurston, G., Jing, C., van Rooijen, E., Kaufman, C. K., et al. (2021) · Oncogene · doi:10.1038/s41388-021-01926-y · Cited by 15

Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently

Kim, S., Park, H.-S., & Oh, B. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.06.021 · Cited by 15

Small molecule SJ572946 activates BAK to initiate apoptosis

Sekar, G., Singh, G., Qin, X., Guibao, C. D., Schwam, B., Inde, Z., Grace, C. R., Zhang, W., Slavish, P. J., Lin, W., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105064 · Cited by 15

High caspase 3 and vulnerability to dual BCL2 family inhibition define ETO2::GLIS2 pediatric leukemia

Aid, Z., Robert, E., Lopez, C. K., Bourgoin, M., Boudia, F., Mene, M. L., Rivière, J., Baille, M., Benbarche, S., Renou, L., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01800-0 · Cited by 15

Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma

Portelinha, A., Ferreira, M. D. S., Erazo, T., Jiang, M., Asgari, Z., de Stanchina, E., Younes, A., & Wendel, H. (2023) · Nature Communications · doi:10.1038/s41467-023-37216-2 · Cited by 15

Mcl-1 Protein and Viral Infections: A Narrative Review

Wyżewski, Z., Stępkowska, J., Kobylińska, A. M., Mielcarska, A., & Mielcarska, M. B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25021138 · Cited by 14

Advances in structural identification of some thieno[2,3-d]pyrimidine scaffolds as antitumor molecules: Synthetic approaches and control programmed cancer cell death potential

Mghwary, A. E.-S., Hassan, R. A., Halim, P. A., & Abdelhameid, M. K. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107985 · Cited by 14

Mcl-1 inhibitor suppresses tumor growth of esophageal squamous cell carcinoma in a mouse model

Lin, J., Fu, D., Dai, Y., Lin, J., & Xu, T. (2017) · Oncotarget · doi:10.18632/oncotarget.18772 · Cited by 14

Myeloid Cell Leukemia 1 Inhibition: An in Silico Study Using Non-equilibrium Fast Double Annihilation Technology

Procacci, P. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00305 · Cited by 14

IL-4 enhances survival of in vitro-differentiated mouse basophils through transcription-independent signaling downstream of PI3K

Reinhart, R., & Kaufmann, T. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-0754-z · Cited by 14

The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance

Zou, J., Jones, R. J., Wang, H., Kuiatse, I., Shirazi, F., Manasanch, E. E., Lee, H. C., Sullivan, R., Fung, L. M., Richard, N., et al. (2020) · Journal of Molecular Medicine · doi:10.1007/s00109-020-01943-6 · Cited by 14

AID overexpression leads to aggressive murine CLL and nonimmunoglobulin mutations that mirror human neoplasms

Morande, P. E., Yan, X., Sepúlveda-Yáñez, J., Seija, N., Márquez, M. E., Sotelo, N. S., Abreu, C., Crispo, M., Fernández-Graña, G., Rego, N., et al. (2021) · Blood · doi:10.1182/blood.2020008654 · Cited by 14

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)

Lapidot, M., Case, A. E., Weisberg, E., Meng, C., Walker, S. R., Garg, S., Wei Min, N. I., Podar, K., Hung, Y. P., Carrasco, R. D., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01441-7 · Cited by 15

Understanding the Species Selectivity of Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors

Zhao, B., Arnold, A. L., Coronel, M. A., Lee, J. H., Lee, T., Olejniczak, E. T., & Fesik, S. W. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00626 · Cited by 14

The Discovery of Cryptic Pockets Increases the Druggability of “Undruggable” Proteins

Mou, M., Yang, W., Huang, G., Yang, X., Zhang, X. L., Kandegama, W., Ashby, C. R., Hao, G., & Gao, Y. (2025) · Medicinal Research Reviews · doi:10.1002/med.70001 · Cited by 14

Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia

Kamachi, K., Ureshino, H., Watanabe, T., Yoshida‐Sakai, N., Fukuda‐Kurahashi, Y., Kawasoe, K., Hoshiko, T., Yamamoto, Y., Kurahashi, Y., & Kimura, S. H. (2023) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0259 · Cited by 13

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

Tiedt, R., King, F. J., Stamm, C., Niederst, M. J., Delach, S. M., Zumstein-Mecker, S., Meltzer, J., Mulford, I. J., Labrot, E., Engstler, B. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112297 · Cited by 13

USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities

Perurena, N., Lock, R., Davis, R. A., Raghavan, S., Pilla, N. F., Ng, R. W. S., Loi, P., Guild, C. J., Miller, A. L., Sicińska, E., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101007 · Cited by 13

MCL1 Can Be Targeted to Induce Apoptosis in Multiple Cancer Types

(2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2016-207

Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models

Maragno, A. L., Mistry, P., Kotschy, A., Szlavik, Z., Murray, J., Davidson, J. E. P., Toumelin-Braizat, G. L., Chanrion, M., Bruno, A., Clapéron, A., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4482 · Cited by 15

Development and Characterization of Novel Mcl-1 Inhibitors for Treatment of Cancer.

Mady, A. S. A. (2016) · Deep Blue (University of Michigan) · Cited by 1

Targeting MCL-1 in cancer: current status and perspectives

Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 318

Targeting MCL‐1 to Overcome Therapeutic Resistance and Improve Cancer Mortality

Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71390 · Cited by 9